The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - A review

Wiener Medizinische Wochenschrift

Volumn 161, Issue 23-24, 2011, Pages 565-570

  Malliga, Daniela Eugenia ^a   Wagner, Doris ^a   Fahrleitner Pammer, Astrid ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Atherosclerosis; Coronary heart disease; Heart failure; Osteoprotegerin; RANKL

Indexed keywords

OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ROSUVASTATIN; UNSATURATED FATTY ACID;

BLOOD VESSEL WALL; HEART LEFT VENTRICLE FAILURE; HEART SURGERY; HUMAN; IMMUNE RESPONSE; METABOLIC BONE DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULITIS;

ADULT; AGE FACTORS; AGED; ARTERIOSCLEROSIS; BONE DENSITY; BONE RESORPTION; CARDIOVASCULAR DISEASES; CORONARY DISEASE; FEMALE; GONADAL STEROID HORMONES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; PROGNOSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SEX FACTORS; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 84857657908     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-011-0022-7     Document Type: Review

References (75)

1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein Involved in the regulation of bone density. Cell, 89: 309-319, 1997. (Pubitemid 27199902)
2. Tsuda E, Goto M, Mochizuki S-I, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun, 234: 137-142, 1997. (Pubitemid 27267548)
3. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 139: 1329-1337, 1998a. (Pubitemid 28510154)
4. Kwon BS, Wang S, Udagawa N, et al. TR1, a newmember of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J, 12: 845-854, 1998. (Pubitemid 28294674)
5. Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNFlike ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and no-hematopoietic cells. Gene, 204: 35-46, 1997. (Pubitemid 28022168)
6. Yun TJ, Chaudhary PM, Shu GL, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol, 161: 6113-6121, 1998. (Pubitemid 28535982)
7. Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol, 166: 1482-1491, 2001. (Pubitemid 32114626)
8. American Society for Bone and Mineral Research President's Committee on Nomenclature. Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. Bone, 27: 761-764, 2000.
9. Hilton MJ, Gutierrez L, Zhang L, et al. An integrated physical map of 8q22-Q24: use in positional cloning and deletion analysis of Langer-Giedion syndrome. Genomics, 71: 192-199, 2001. (Pubitemid 32165086)
10. Morinaga T, Nakagawa N, Yasuda H, et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem, 254: 685-691, 1998. (Pubitemid 28308123)
11. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci, 95: 3597-3602, 1998b.
12. Merewether LA, Le J, Jones MD, et al. Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. Arch Biochem Biophys, 375: 101-110, 2000. (Pubitemid 30133626)
13. Tomoyasu A, Goto M, Fujise N, et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun, 245: 382-387, 1998. (Pubitemid 28418509)
14. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem, 273: 5117-5123, 1998. (Pubitemid 28108672)
15. Leibbrandt A, Penninger JM. RANK/RANKL: Regulators of immune responses and bone physiology. Ann NY Acad Sci, 1143: 123-150, 2008.
16. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene, 17: 3261-3270, 1998. (Pubitemid 29043978)
17. Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165-176, 1998. (Pubitemid 28180851)
18. Emery JG, McDonnell P, Brigham Burke M, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 273: 14363-14367, 1998. (Pubitemid 28319153)
19. Wagner D, Fahrleitner-Pammer A. Levels of osteoprotegerin (OPG) and receptor activator for factor kappa ligand (RANKL) in serum: are they of any help. Wien Med Wochenschr, 160: 452-457, 2010.
20. Fahrleitner-Pammer A, Herberth J, Browning SR, et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res, 23: 1850-1858, 2008.
21. Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med, 188: 997-1001, 1998. (Pubitemid 28433427)
22. Quinn JMW, Elliott J, Gillespie MT, et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology, 139: 4424-4427, 1998. (Pubitemid 28513734)
23. Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kb ligand. Bone, 25: 517-523, 1999. (Pubitemid 29469457)
24. Xu J, Tan JW, Huang L, et al. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kb ligand. J Bone Miner Res, 15: 2178-2186, 2000.
25. Dobnig H, Hofbauer LC, Viereck V, et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in biphosphanate-treated osteoporotic patients. Osteoporos Int, 17: 693-703, 2006.
26. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12: 1260-1268, 1998. (Pubitemid 28213402)
27. Venuraju SM, Yerramasu A, Corder R, et al. Osteprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol, 55: 2049-2061, 2010.
28. Price P, June HH, Buckley JR, et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin B. Arterioscler Thromb vasc Biol, 21: 1610-1616, 2001. (Pubitemid 34215580)
29. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun, 247: 610-615, 1998. (Pubitemid 28418439)
30. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation, 117: 411-420, 2008.
31. O'Sullivan EP, Ashley DT, Davenport C, et al. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab Res Rev, 26: 496-502, 2010.
32. Zagura M, Serg M, Kampus P, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens, 23: 586-591, 2010.
33. Crisafulli A, Micari A, Altavilla D, et al. Serum level of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clinical Science, 109: 389-395, 2005. (Pubitemid 41445246)
34. Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL systems. Common mechanism of osteoporosis and vascular calcification. Circ Res, 107: 466-475, 2010.
35. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentration in postmenopausal women with osteoporosis. J Bone Miner Res, 14: 518-527, 1999. (Pubitemid 29153384)
36. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 109: 2175-2180, 2004. (Pubitemid 38625393)
37. Clancy P, Oliver L, Jayalath R, et al. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol, 26: 2574-2576, 2006. (Pubitemid 44607454)
38. Gogo P, SSchneider DJ, Terrien EF, et al. Osteoprotegerin is not associated with angiographic coronary calcification. J Thromb Thrombolysis, 22: 177-183, 2006. (Pubitemid 44857778)
39. Sandberg WJ, Yndestad A, Oie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome. Possible role in plaque destabilization. Arterioscler Thromb Vasc Biol, 26: 857-863, 2006. (Pubitemid 43732163)
40. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care, 29: 1664-1666, 2006.
41. Rasmussen LM, Tarnow L, Hansen TK, et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrin, 154: 75-81, 2006. (Pubitemid 43250739)
42. Xiang G, Xu L, Zhao LS, et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, 55: 2126-2131, 2006. (Pubitemid 44509988)
43. Anand DV, Lahiri A, Lim E, et al. The Relationship between plasma Osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. JACC, 47: 1850-1857, 2006.
44. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel independent marker for silentmyocardial ischemic in asymptomatic diabetic patients. Diabetes Care, 30: 2934-2939, 2007. (Pubitemid 350083147)
45. Xiang GD, Xu L, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Zhonghua Yi Xue Za Zhi, 87: 1234-1237, 2007. (Pubitemid 47073168)
46. Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes. Role of glycemic control and inflammatory/vascular calcification markers. JACC, 50: 2218-2225, 2007. (Pubitemid 350166815)
47. Asanuma Y, Chung CP, Oeser A, et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 195: e135-e141, 2007. (Pubitemid 350087969)
48. Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaques (from the DALAS heart study). Am J Cardiol, 99: 513-519, 2007.
49. Helske S, Kovanen PT, Lindstedt KA, et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular overload. Eur J Heart Fail, 9: 357-363, 2007. (Pubitemid 46441975)
50. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension, 49: 1392-1398, 2007. (Pubitemid 46809385)
51. Kiechl S, Schett G, Schwaiger J, et al. Soluble Receptor activator of nuclear factor-B ligand and risk for cardiovascular disease. Circulation, 116: 385-391, 2007. (Pubitemid 47196543)
52. Kadoglou NP, Gerasimidis T, Golemati S, et al. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg, 47: 55-62, 2008.
53. Siepi D, Marchesi S, Vaudo G, et al. Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin. Metab Clin Exper, 57: 321-325, 2008. (Pubitemid 351178720)
54. Golledge J, Leicht AS, Crowther RG, et al. Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiology, 111: 51-56, 2008.
55. Semb AG, Ueland T, Aukrust P, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-B ligand and risk for coronary events. A nested case-control approach in the prospective EPICNorfolk population study 1993-2003. Artherioscler Thromb Vasc Biol, 29: 975-980, 2009.
56. Kong Y-Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397: 315-323, 1999a.
57. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab, 88: 1024-1028, 2003. (Pubitemid 36337751)
58. Gannage-Yared MH, Fares F, Semaan M, et al. Circulation Osteoprotegerin is correlated with lipid profile, insulin sensivity, adiponectin and sex steroids in an ageing male population. Clin Endocrin (Oxf), 64: 652-658, 2006. (Pubitemid 43775003)
59. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 106: 1192-1194, 2002. (Pubitemid 34988634)
60. Khosla S, Arrighi HM, Melton LJ 3rd, et al. Correlates of osteoprotegerin levels in women and men. Osteopor Int, 13: 394-399, 2002. (Pubitemid 34625396)
61. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet, 358: 257-259, 2001c.
62. Ho KK, Anderson KM, Grossman W, et al. Survival after the onset of congenitiv heart failure in Framingham heart study. Circlation, 88: 107-115, 1993. (Pubitemid 23195439)
63. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res, 91: 988-998, 2002. (Pubitemid 35416635)
64. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol, 274: R577-595, 1998.
65. Yndestad A, Damas JK, Geir EH, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res, 54: 175-182, 2002.
66. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation, 111: 2461-2468, 2005. (Pubitemid 40696134)
67. Yan ET, Yan RT, Spinale FG, et al. Relationship between plasma levels of matrix metalloproteinase and neurohormonal profile in patients with heart failure. Eur J Heart Fail, 10: 125-128, 2008.
68. Liu W, Feng W, Wang F, et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol, 84: 213-217, 2008.
69. Omland T, Ueland T, Jansson AM, et al. Circulation osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol, 51:627-633, 2008. (Pubitemid 351193104)
70. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acutemyocardial infarction. J Am Coll Cardiol, 44: 1970-1976, 2004. (Pubitemid 39473280)
71. Roysland R, Masson S, Omland T, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J, 160: 286-293, 2010.
72. Lieb W, Gona P, Larson MG, et al. Biomarkers of osteoprotegerin pathway clinical correlates, subclinical disease, incident cardiovascular disease and mortality. Arterioscler Thromb Vasc Biol, 30: 1849-1854, 2010.
73. Ueland T, Dahl CP, Kjekshus J, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail, 4(2): 145-152, 2011.
74. Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol, 143: 31-48, 2007. (Pubitemid 46625234)
75. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrin, 159: 603-608, 2008.